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Dear Editor,
The diagnosis of cryptogenic cirrhosis is an exclusion 
diagnosis. It has become far less frequent over the last de-
cades, but it still eﬀects a signiﬁcant number of patients. 
Many previously unknown chronic liver disease entities 
were described in the second half of the last century, in-
cluding chronic viral hepatitis B, C and D, along with re-
ﬁned criteria for diagnosing autoimmune hepatitis and 
insights into the pathogenesis and disease progression 
of fatty liver disease (1). Although hemochromatosis, and 
its pathophysiology were not understood until cloning 
of the HFE-gene (2), it has been known as a chronic liver 
disease for a long time, although it may be under-recog-
nized due to the lack of speciﬁc symptoms and thus con-
tribute to cases of cryptogenic cirrhosis. 
Jowkar et al. (3) described the frequency of the most 
common disease-causing mutations of the HFE-gene 
(C282Y and H63D) in Iranian patients with cryptogenic 
cirrhosis and healthy controls. They did not observe any 
C282Y mutations and only heterozygous H63D muta-
tions were found in about one quarter of both healthy 
and cirrhotic patients. As the C282Y mutation is most 
likely to be of northern European origin, the low fre-
quency found in the present report is not surprising. The 
H63D mutation however, was present heterozygous in 
almost one quarter of the patients without any of these 
patients carrying homozygous mutations, this is surpris-
ing and much higher than would be expected (4, 5). As 
there were no diﬀerences between healthy controls and 
cirrhotic patients, these numbers most likely reﬂect 
the allele frequency in the general Iranian population 
and were described for the ﬁrst time in the current re-
port. The authors present results for patients with and 
without iron overload. Unfortunately, the numbers of 
patients diagnosed with iron overload are not reported. 
Therefore, the relative proportion of patients carrying 
the H63D mutation cannot be calculated and the im-
pact of iron overload on cryptogenic cirrhosis cannot 
be deduced. Furthermore, iron overload in the paper by 
Jowkar et al. has been deﬁned by transferrin saturation. It 
would be valuable to know serum-ferritin levels in order 
to get further insights into the state of iron metabolism. 
Classic HFE related hemochromatosis, as demonstrated 
by the authors, is extremely unlikely in this population. 
If iron overload were indeed present it would be worth-
while testing for other hemochromatosis associated 
mutations, namely transferrin receptor 2 (tfr2) and fer-
roportin (fpn) (6). 
In conclusion, Jowkar et al. conﬁrmed the low frequen-
cy of hemochromatosis causing HFE mutations in the 
Iranian population for the ﬁrst time. Further studies are 
still needed to evaluate the impact of hereditary iron me-
tabolism disorders on cryptogenic cirrhosis in Iran.210 Hepat Mon. 2012
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